Authors:
Mundhenke, C
Thomas, JP
Wilding, G
Lee, FT
Kelzc, F
Chappell, R
Neider, R
Sebree, LA
Friedl, A
Citation: C. Mundhenke et al., Tissue examination to monitor antiangiogenic therapy: A phase I clinical trial with endostatin, CLIN CANC R, 7(11), 2001, pp. 3366-3374
Authors:
Sax, H
Friedl, A
Renner, E
Steuerwald, MH
Weber, R
Citation: H. Sax et al., Pilot study of interferon-alpha with and without amantadine for the treatment of hepatitis C in HIV co-infected individuals on antiretroviral therapy, INFECTION, 29(5), 2001, pp. 267-270
Authors:
Chang, Z
Meyer, K
Rapraeger, AC
Friedl, A
Citation: Z. Chang et al., Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ, FASEB J, 14(1), 2000, pp. 137-144
Authors:
Kinoshita, H
Shi, Y
Sandefur, C
Meisner, LF
Chang, CS
Choon, A
Reznikoff, CR
Bova, GS
Friedl, A
Jarrard, DF
Citation: H. Kinoshita et al., Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer, CANCER RES, 60(13), 2000, pp. 3623-3630
Authors:
Friedl, A
Stoesz, SP
Buckley, P
Gould, MN
Citation: A. Friedl et al., Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression, HISTOCHEM J, 31(7), 1999, pp. 433-441
Citation: Z. Chang et al., Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding, AM J PATH, 155(1), 1999, pp. 71-76